Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
Date: September 23, 2019
Issue #:
1581Summary:
The FDA has approvedDuaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be
approved in the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Anoro Ellipta Bevespi Aerosphere COPD Duaklir Pressair Formoterol Glycopyrrolate indacaterol Inspiolto Respimat Long-acting beta2-agonists Stiolto Respimat tiotropium/olodaterol Ultibro Breezehaler umeclidinium Utibr Source Type: research
More News: Aclidinium Bromide | Chronic Obstructive Pulmonary | Drugs & Pharmacology | Spiriva | Tiotropium